DermTech, Inc.
DermTech, Inc. (DMTK) Stock Overview
Explore DermTech, Inc.’s financial performance, market position, analyst ratings, and future outlook.
DMTK Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of DermTech, Inc. (DMTK) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $0.03.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.08 and a market capitalization of 3.3M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Company Profile
DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. It offers DermTech Melanoma Test (DMT), a gene expression test that enhances early detection of genomic atypia and helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. The company also provides adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. In addition, it is developing UV damage DNA risk assessment products, as well as non-melanoma skin cancer diagnostic and cutaneous T-cell lymphoma rule out test products, as well as offering health-related and information services through electronic information and telecommunication technologies. The company sells its products primarily to pathology and oncology practitioners. DermTech, Inc. is headquartered in La Jolla, California.
Mr. Bret Christensen
206
11099 North Torrey Pines Road, La Jolla, CA
2017